Published in J Cereb Blood Flow Metab on September 01, 1983
Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging (2005) 3.32
Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage (2009) 2.80
Combining MR imaging, positron-emission tomography, and CSF biomarkers in the diagnosis and prognosis of Alzheimer disease. AJNR Am J Neuroradiol (2010) 2.61
PGC-1alpha expression decreases in the Alzheimer disease brain as a function of dementia. Arch Neurol (2009) 1.61
Methylthioninium chloride reverses cognitive deficits induced by scopolamine: comparison with rivastigmine. Psychopharmacology (Berl) (2008) 1.02
Gray matter network associated with risk for Alzheimer's disease in young to middle-aged adults. Neurobiol Aging (2012) 1.00
Understanding dementia prevalence among centenarians. J Gerontol A Biol Sci Med Sci (2012) 0.99
Brain functional network in Alzheimer's disease: diagnostic markers for diagnosis and monitoring. Int J Alzheimers Dis (2011) 0.91
Focal cerebral hypoperfusion and selective cognitive deficit in dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry (1987) 0.90
The Basic Biology of BACE1: A Key Therapeutic Target for Alzheimer's Disease. Curr Genomics (2007) 0.90
A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis. Biomed Res Int (2014) 0.85
Using biomarkers to improve detection of Alzheimer's disease. Neurodegener Dis Manag (2011) 0.84
Functional and neurobiological similarities of aging in monkeys and humans. Age (Omaha) (1997) 0.84
Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia. Neuropsychiatr Dis Treat (2011) 0.83
Decline in cerebral glucose utilisation and cognitive function with aging in Down's syndrome. J Neurol Neurosurg Psychiatry (1987) 0.82
Dominantly inherited Alzheimer's disease: cerebral glucose metabolism. J Neurol Neurosurg Psychiatry (1987) 0.80
Intracerebroventricular streptozotocin exacerbates Alzheimer-like changes of 3xTg-AD mice. Mol Neurobiol (2013) 0.79
Comparing fludeoxyglucose F18-PET assessment of regional cerebral glucose metabolism and [11C]dihydrotetrabenazine-PET in evaluation of early dementia and mild cognitive impairment. Arch Neurol (2010) 0.79
The concept of FDG-PET endophenotype in Alzheimer's disease. Neurol Sci (2011) 0.77
Cerebral metabolism, anatomy, and cognition in monozygotic twins discordant for dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry (1987) 0.77
Comparability of [(18)F]THK5317 and [(11)C]PIB blood flow proxy images with [(18)F]FDG positron emission tomography in Alzheimer's disease. J Cereb Blood Flow Metab (2016) 0.77
Behavioral and omics analyses study on potential involvement of dipeptide balenine through supplementation in diet of senescence-accelerated mouse prone 8. Genom Data (2016) 0.75
The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry (1982) 10.83
Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab (1990) 6.62
Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. JAMA (2001) 5.13
A family intervention to delay nursing home placement of patients with Alzheimer disease. A randomized controlled trial. JAMA (1996) 4.80
Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 4.31
Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers. Synapse (1993) 4.13
Hippocampal and entorhinal atrophy in mild cognitive impairment: prediction of Alzheimer disease. Neurology (2007) 3.97
Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A (2001) 3.86
Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 3.77
Functional assessment staging (FAST). Psychopharmacol Bull (1988) 3.42
The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience (2000) 3.40
Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging (2001) 3.25
Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment. Neurobiol Aging (2005) 3.00
Changes in brain glucose metabolism in cocaine dependence and withdrawal. Am J Psychiatry (1991) 2.89
Mild cognitive impairment in the elderly: predictors of dementia. Neurology (1991) 2.83
Atrophy of the medial occipitotemporal, inferior, and middle temporal gyri in non-demented elderly predict decline to Alzheimer's disease. Neurobiol Aging (2000) 2.80
Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology (2009) 2.76
Frequency of hippocampal formation atrophy in normal aging and Alzheimer's disease. Neurobiol Aging (1997) 2.68
Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. Neurology (2008) 2.66
Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry (1987) 2.65
MR of spinal cord ganglioglioma. AJNR Am J Neuroradiol (1998) 2.63
Inhibition of monoamine oxidase B in the brains of smokers. Nature (1996) 2.62
Hippocampal volumes in cognitively normal persons at genetic risk for Alzheimer's disease. Ann Neurol (1998) 2.48
The radiologic prediction of Alzheimer disease: the atrophic hippocampal formation. AJNR Am J Neuroradiol (1993) 2.44
Hippocampal volume losses in minimally impaired elderly. Lancet (1995) 2.26
Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. Radiology (1999) 2.26
A comprehensive support program: effect on depression in spouse-caregivers of AD patients. Gerontologist (1995) 2.26
Reduced hippocampal metabolism in MCI and AD: automated FDG-PET image analysis. Neurology (2005) 2.24
Long-term frontal brain metabolic changes in cocaine abusers. Synapse (1992) 2.16
Global Deterioration Scale (GDS). Psychopharmacol Bull (1988) 2.14
Altered glucose metabolism in microvessels from patients with Alzheimer's disease. Ann Neurol (1989) 2.08
Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med (1978) 2.07
Early marker for Alzheimer's disease: the atrophic hippocampus. Lancet (1989) 2.02
A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection. J Nucl Med (1980) 2.01
Glucose utilization of cerebral gliomas measured by [18F] fluorodeoxyglucose and positron emission tomography. Neurology (1982) 1.99
Neuropsychological prediction of decline to dementia in nondemented elderly. J Geriatr Psychiatry Neurol (1999) 1.93
Alzheimer disease: measuring loss of cerebral gray matter with MR imaging. Radiology (1991) 1.92
MRI of entorhinal cortex in mild Alzheimer's disease. Lancet (1999) 1.86
Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease. Neurology (2004) 1.86
Is [1-11C]putrescine useful as a brain tumor marker? J Nucl Med (1992) 1.80
Brain monoamine oxidase A inhibition in cigarette smokers. Proc Natl Acad Sci U S A (1996) 1.78
MRI and CSF studies in the early diagnosis of Alzheimer's disease. J Intern Med (2004) 1.77
An intervention that delays institutionalization of Alzheimer's disease patients: treatment of spouse-caregivers. Gerontologist (1993) 1.72
Relationships between regional neuronal loss and neurofibrillary changes in the hippocampal formation and duration and severity of Alzheimer disease. J Neuropathol Exp Neurol (1997) 1.67
Effects of chronic cocaine abuse on postsynaptic dopamine receptors. Am J Psychiatry (1990) 1.66
CT diagnostic features of Alzheimer disease: importance of the choroidal/hippocampal fissure complex. AJNR Am J Neuroradiol (1990) 1.62
Evaluation of pediatric hydrocephalus by computed tomography. Radiology (1976) 1.60
Dementia: a systematic approach to identifying reversible causes. Geriatrics (1986) 1.55
Brief Cognitive Rating Scale (BCRS). Psychopharmacol Bull (1988) 1.55
Functional assessment staging (FAST) in Alzheimer's disease: reliability, validity, and ordinality. Int Psychogeriatr (1992) 1.54
Intersubject variability of brain glucose metabolic measurements in young normal males. J Nucl Med (1994) 1.54
The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord (1997) 1.53
The effects of mood changes and antidepressants on the cognitive capacity of elderly depressed patients. Int Psychogeriatr (1989) 1.50
Hippocampal atrophy in normal aging. An association with recent memory impairment. Arch Neurol (1993) 1.49
Diminished cerebral metabolic response to motor stimulation in schizophrenics: a PET study. Eur Arch Psychiatry Clin Neurosci (1994) 1.48
Ocular lesions associated with HIV infection in India: a series of 100 consecutive patients evaluated at a referral center. Am J Ophthalmol (2000) 1.47
ON THE MECHANISM OF ACTION OF THE ANTIDIURETIC HORMONE (VASOPRESSIN). Proc Natl Acad Sci U S A (1960) 1.43
Age associated memory impairment. BMJ (1992) 1.41
Serial [18F]N-methylspiroperidol PET studies to measure changes in antipsychotic drug D-2 receptor occupancy in schizophrenic patients. Biol Psychiatry (1988) 1.40
Patterns of motor impairement in normal aging, mild cognitive decline, and early Alzheimer's disease. J Gerontol B Psychol Sci Soc Sci (1997) 1.39
Medical and economic benefit of a comprehensive infection control program that includes routine determination of microbial clonality. Am J Clin Pathol (1999) 1.39
Volumetric analysis of the pre-frontal regions: findings in aging and schizophrenia. Psychiatry Res (2001) 1.38
Hippocampal atrophy in early Alzheimer's disease: anatomic specificity and validation. Psychiatr Q (1993) 1.33
Hypersensitivity to scopolamine in the elderly. Psychopharmacology (Berl) (1992) 1.33
Hippocampal formation size predicts declining memory performance in normal aging. Neurology (1996) 1.33
Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications. Arch Neurol (1992) 1.33
Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology (1982) 1.31
Atrophy rate in medial temporal lobe during progression of Alzheimer disease. Neurology (2004) 1.31
Hippocampal formation size in normal human aging: a correlate of delayed secondary memory performance. Learn Mem (1999) 1.31